Pediatric Epilepsy Study in Subjects 1-24 Months

January 16, 2017 updated by: GlaxoSmithKline

An Open-Label, Uncontrolled, Long-Term Study to Assess the Safety of LAMICTAL in Pediatric Subjects Previously Enrolled in Protocol LAM20006 and In LAMICTAL-naive Subjects (1-24 Months of Age)

This study will evaluate the long-term safety of LAMICTAL(lamotrigine)in subjects with partial seizures previously enrolled in protocol LAM20006 and in subjects 1-24 months of age who have never received LAMICTAL(LAMICTAL-naive). For LAMICTAL-naive subjects, LAMICTAL will be added to the subject's current epilepsy medications.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
197

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Argentina
      • Ciudad Autónoma de Buenos Aires, Argentina, 1425
        • GSK Investigational Site
    • Buenos Aires
      • Capital Federal, Buenos Aires, Argentina, 1181
        • GSK Investigational Site
  • Australia
    • Victoria
      • Parkville, Melbourne, Victoria, Australia, 3050
        • GSK Investigational Site
  • Estonia
      • Tartu, Estonia, 51014
        • GSK Investigational Site
  • France
      • Reims Cedex, France, 51092
        • GSK Investigational Site
  • Hungary
      • Budapest, Hungary, 1094
        • GSK Investigational Site
      • Debrecen, Hungary, 4012
        • GSK Investigational Site
      • Miskolc, Hungary, 3526
        • GSK Investigational Site
      • Pécs, Hungary, 7623
        • GSK Investigational Site
      • Szeged, Hungary, 6720
        • GSK Investigational Site
  • Italy
    • Campania
      • Napoli, Campania, Italy, 80131
        • GSK Investigational Site
    • Emilia-Romagna
      • Bologna, Emilia-Romagna, Italy, 40138
        • GSK Investigational Site
    • Lombardia
      • Mantova, Lombardia, Italy, 46100
        • GSK Investigational Site
      • Milano, Lombardia, Italy, 20133
        • GSK Investigational Site
    • Sicilia
      • Messina, Sicilia, Italy, 98125
        • GSK Investigational Site
    • Veneto
      • Padova, Veneto, Italy, 35128
        • GSK Investigational Site
  • Latvia
      • Riga, Latvia, LV 1004
        • GSK Investigational Site
  • Lebanon
      • Beirut, Lebanon, 11072020
        • GSK Investigational Site
  • Lithuania
      • Kaunas, Lithuania, LT-50009
        • GSK Investigational Site
  • Netherlands
      • Groningen, Netherlands, 9713 GZ
        • GSK Investigational Site
      • Rotterdam, Netherlands, 3015 GD
        • GSK Investigational Site
      • Utrecht, Netherlands, 3584 EA
        • GSK Investigational Site
  • Portugal
      • Coimbra, Portugal, 3000-075
        • GSK Investigational Site
      • Lisboa, Portugal, 1150
        • GSK Investigational Site
      • Porto, Portugal, 4099-001
        • GSK Investigational Site
  • Puerto Rico
      • SanJuan, Puerto Rico, 00936
        • GSK Investigational Site
  • Slovakia
      • Bratislava, Slovakia, 833 40
        • GSK Investigational Site
      • Presov, Slovakia, 080 01
        • GSK Investigational Site
  • Turkey
      • Ankara, Turkey
        • GSK Investigational Site
  • United States
    • Alabama
      • Mobile, Alabama, United States, 36693
        • GSK Investigational Site
    • Arizona
      • Tucson, Arizona, United States, 85712
        • GSK Investigational Site
    • Arkansas
      • Jonesboro, Arkansas, United States, 72401
        • GSK Investigational Site
      • Little Rock, Arkansas, United States, 72202
        • GSK Investigational Site
    • California
      • Los Angeles, California, United States, 90095
        • GSK Investigational Site
      • Los Angeles, California, United States, 90027
        • GSK Investigational Site
      • Stanford, California, United States, 94305-5235
        • GSK Investigational Site
    • Colorado
      • Denver, Colorado, United States, 80218
        • GSK Investigational Site
    • District of Columbia
      • Washington, District of Columbia, United States, 20010
        • GSK Investigational Site
    • Florida
      • Jacksonville, Florida, United States, 32207
        • GSK Investigational Site
      • Miami, Florida, United States, 33155-3009
        • GSK Investigational Site
      • Orlando, Florida, United States, 32835
        • GSK Investigational Site
      • Tallahassee, Florida, United States, 32308
        • GSK Investigational Site
      • Tampa, Florida, United States, 33609
        • GSK Investigational Site
    • Georgia
      • Atlanta, Georgia, United States, 30342
        • GSK Investigational Site
      • Augusta, Georgia, United States, 30912
        • GSK Investigational Site
    • Kentucky
      • Lexington, Kentucky, United States, 40536-0284
        • GSK Investigational Site
    • Minnesota
      • St. Paul, Minnesota, United States, 55102-2383
        • GSK Investigational Site
    • Missouri
      • Columbia, Missouri, United States, 65211
        • GSK Investigational Site
      • Kansas City, Missouri, United States, 64108
        • GSK Investigational Site
    • New Jersey
      • Cherry Hill, New Jersey, United States, 8034
        • GSK Investigational Site
    • New York
      • Buffalo, New York, United States, 14222
        • GSK Investigational Site
      • Mineola, New York, United States, 11501
        • GSK Investigational Site
      • Syracuse, New York, United States, 13210
        • GSK Investigational Site
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • GSK Investigational Site
      • Raleigh, North Carolina, United States, 27607
        • GSK Investigational Site
    • Ohio
      • Akron, Ohio, United States, 44308-1062
        • GSK Investigational Site
      • Cleveland, Ohio, United States, 44106
        • GSK Investigational Site
      • Columbus, Ohio, United States, 43205
        • GSK Investigational Site
    • Oregon
      • Portland, Oregon, United States, 97201-2884
        • GSK Investigational Site
      • Portland, Oregon, United States, 97201-2984
        • GSK Investigational Site
    • Pennsylvania
      • Pittsburgh, Pennsylvania, United States, 15213-2583
        • GSK Investigational Site
    • Tennessee
      • Morristown, Tennessee, United States, 37813
        • GSK Investigational Site
      • Nashville, Tennessee, United States, 37212
        • GSK Investigational Site
    • Texas
      • Dallas, Texas, United States, 75230
        • GSK Investigational Site
      • Fort Worth, Texas, United States, 76104
        • GSK Investigational Site
      • Houston, Texas, United States, 77030
        • GSK Investigational Site
    • Utah
      • Salt Lake City, Utah, United States, 84113
        • GSK Investigational Site
    • Virginia
      • Charlottesville, Virginia, United States, 22908
        • GSK Investigational Site
      • Norfolk, Virginia, United States, 23507
        • GSK Investigational Site
      • Richmond, Virginia, United States, 23298
        • GSK Investigational Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

1 month to 2 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion criteria:

  • Must have completed the Open-Label Phase of protocol LAM20006 or meet criteria for LAMICTAL naive subjects as follows:
  • A confident diagnosis of epilepsy.
  • 4 or more partial seizures per month.
  • current treatment with 1 or 2 anti-epileptic drugs.

Exclusion criteria:

  • Has seizures not related to epilepsy.
  • Has a surgically implanted and functioning vagal nerve stimulator.
  • Has previously been treated with lamotrigine.
  • Is currently taking felbamate, ACTH (adrenocorticotrophic hormone) or is on the ketogenic diet.
  • Use of experimental medication within 30 days of enrollment.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Number of participants with overall, serious, drug-related treatment emergent adverse events and adverse events leading to premature study discontinuation
Time Frame: 43 Months
43 Months
Change from baseline in vital signs -heart rate (HR)
Time Frame: Up to 43 Months
Up to 43 Months
Change from baseline in vital signs - weight (WT)
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in vital signs - height (HT)
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in vital signs - head circumference (HC)
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in clinical chemistry parameters including Albumin and Total protein
Time Frame: Up to month 43
Up to month 43
Change from baseline in clinical chemistry parameters including alkaline phosphatase, Alanine transaminase (ALT), and Aspartate Aminotransferase (AST)
Time Frame: Up to 43 moths
Up to 43 moths
Change from baseline in clinical chemistry parameters including total bilirubin and creatinine
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in clinical chemistry parameters including glucose (glu), potassium (K), sodium (Na) and urea
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in hematological parameters including bands, basophils, eosinophils, lymphocytes, monocytes, neutrophils, platelets and total white blood cells (WBC)
Time Frame: Up to 43 moths
Up to 43 moths
Change from baseline in Hemoglobin (Hb)
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in Mean corpuscular hemoglobin (MCH)
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in Mean corpuscular hemoglobin concentration (MCHC)
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in mean corpuscular volume (MCv)
Time Frame: Up to 43 months
Up to 43 months
Change from baseline in red blood cells (RBC)
Time Frame: Up to 43 months
Up to 43 months
Number of participants with treatment emergent neurological abnormalities
Time Frame: Up to 43 months
Up to 43 months
Number of participants with treatment emergent clinically significant ECG abnormalities
Time Frame: Up to 43 months
Up to 43 months
Number of participants with potentially clinically significant change in hematology parameters
Time Frame: Up to 43 months
Up to 43 months
Number of participants with potentially clinically significant change in clinical chemistry parameters
Time Frame: Up to 43 months
Up to 43 months
Number of participants with potentially clinically significant change in vital signs
Time Frame: Up to 43 months
Up to 43 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Mean percentage change in seizure frequency between the Historical Baseline Phase and over the course of the 48-week Treatment Phase
Time Frame: Up to 48 Weeks
Up to 48 Weeks
Investigator's assessment of the participant's overall clinical status
Time Frame: Up to 43 months
Up to 43 months
Mean Maximal plasma concentration (Cmax) in serum and saliva of Lamicital -naïve participants
Time Frame: Week 6
Week 6

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
GlaxoSmithKline

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
September 1, 2000

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
June 1, 2006

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
June 1, 2006

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
August 23, 2002

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
August 23, 2002

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
August 26, 2002

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
January 18, 2017

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 16, 2017

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
January 1, 2017

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • LAM20007

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

Study Data/Documents

  1. Annotated Case Report Form
    Information identifier: LAM20007
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  2. Clinical Study Report
    Information identifier: LAM20007
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  3. Dataset Specification
    Information identifier: LAM20007
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  4. Informed Consent Form
    Information identifier: LAM20007
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  5. Study Protocol
    Information identifier: LAM20007
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  6. Statistical Analysis Plan
    Information identifier: LAM20007
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register
  7. Individual Participant Data Set
    Information identifier: LAM20007
    Information comments: For additional information about this study please refer to the GSK Clinical Study Register

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings